Growth Hormone Insensitivity

Arlan L. Rosenbloom; Timothy P. Foster; Michael Haller; Jaime Guevara-Aguirre

doi:10.1007/978-3-031-66296-6_2

Growth Hormone Insensitivity

Arlan L. Rosenbloom
, Timothy P. Foster
, Michael Haller
, Jaime Guevara-Aguirre

Medicina

University of Florida

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Growth hormone insensitivity (GHI) or resistance is the absence of a growth or metabolic response to endogenous GH produced by the liver or to recombinant human (rh) GH administered in physiologic doses. Genetic disorders that result in GHI are rare and include GH receptor deficiency (GHRD, Laron syndrome), as well as mutations affecting genes of signal transducer and activator of transcription 5B (STAT5b), protein tyrosine phosphatase nonreceptor type 11 (PTPN11), acid labile subunit (ALS), insulin-like growth factor-I (IGF-I), the IGF-I receptor, and pappalysin 2 (PAPP-A2). Limited experience with rhIGF-I therapy in GHRD demonstrates restoration of growth that is less than seen with rhGH replacement in GH deficiency, probably due to the absence of direct effects of GH in bone and muscle.

Original language	English
Title of host publication	Pediatric Endocrinology
Subtitle of host publication	A Practical Clinical Guide, Fourth Edition
Publisher	Springer Nature
Pages	35-72
Number of pages	38
ISBN (Electronic)	9783031662966
ISBN (Print)	9783031662959
DOIs	https://doi.org/10.1007/978-3-031-66296-6_2
State	Published - 1 Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acid labile subunit (ALS)
GH-binding protein (BP)
GHR gene mutation
Growth hormone (GH)
Insulin-like growth factor-I (IGF-I)
Laron syndrome
Noonan syndrome
Pappalysin 2 (PAPP-A2)
Protein tyrosine phosphatase non-receptor type 11 (PTPN11)
Receptor (R)
Recombinant human IGF-I (rhIGF-I)
Serum transducers and activators of transcription 5b (STAT5b)

Access to Document

10.1007/978-3-031-66296-6_2

Cite this

@inbook{43418265a0444fb6a23231edbc2f59d2,

title = "Growth Hormone Insensitivity",

abstract = "Growth hormone insensitivity (GHI) or resistance is the absence of a growth or metabolic response to endogenous GH produced by the liver or to recombinant human (rh) GH administered in physiologic doses. Genetic disorders that result in GHI are rare and include GH receptor deficiency (GHRD, Laron syndrome), as well as mutations affecting genes of signal transducer and activator of transcription 5B (STAT5b), protein tyrosine phosphatase nonreceptor type 11 (PTPN11), acid labile subunit (ALS), insulin-like growth factor-I (IGF-I), the IGF-I receptor, and pappalysin 2 (PAPP-A2). Limited experience with rhIGF-I therapy in GHRD demonstrates restoration of growth that is less than seen with rhGH replacement in GH deficiency, probably due to the absence of direct effects of GH in bone and muscle.",

keywords = "Acid labile subunit (ALS), GH-binding protein (BP), GHR gene mutation, Growth hormone (GH), Insulin-like growth factor-I (IGF-I), Laron syndrome, Noonan syndrome, Pappalysin 2 (PAPP-A2), Protein tyrosine phosphatase non-receptor type 11 (PTPN11), Receptor (R), Recombinant human IGF-I (rhIGF-I), Serum transducers and activators of transcription 5b (STAT5b)",

author = "Rosenbloom, \{Arlan L.\} and Foster, \{Timothy P.\} and Michael Haller and Jaime Guevara-Aguirre",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2003, 2013, 2018, 2024.",

year = "2024",

month = jan,

day = "1",

doi = "10.1007/978-3-031-66296-6\_2",

language = "Ingl{\'e}s",

isbn = "9783031662959",

pages = "35--72",

booktitle = "Pediatric Endocrinology",

publisher = "Springer Nature",

}

TY - CHAP

T1 - Growth Hormone Insensitivity

AU - Rosenbloom, Arlan L.

AU - Foster, Timothy P.

AU - Haller, Michael

AU - Guevara-Aguirre, Jaime

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2003, 2013, 2018, 2024.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Growth hormone insensitivity (GHI) or resistance is the absence of a growth or metabolic response to endogenous GH produced by the liver or to recombinant human (rh) GH administered in physiologic doses. Genetic disorders that result in GHI are rare and include GH receptor deficiency (GHRD, Laron syndrome), as well as mutations affecting genes of signal transducer and activator of transcription 5B (STAT5b), protein tyrosine phosphatase nonreceptor type 11 (PTPN11), acid labile subunit (ALS), insulin-like growth factor-I (IGF-I), the IGF-I receptor, and pappalysin 2 (PAPP-A2). Limited experience with rhIGF-I therapy in GHRD demonstrates restoration of growth that is less than seen with rhGH replacement in GH deficiency, probably due to the absence of direct effects of GH in bone and muscle.

AB - Growth hormone insensitivity (GHI) or resistance is the absence of a growth or metabolic response to endogenous GH produced by the liver or to recombinant human (rh) GH administered in physiologic doses. Genetic disorders that result in GHI are rare and include GH receptor deficiency (GHRD, Laron syndrome), as well as mutations affecting genes of signal transducer and activator of transcription 5B (STAT5b), protein tyrosine phosphatase nonreceptor type 11 (PTPN11), acid labile subunit (ALS), insulin-like growth factor-I (IGF-I), the IGF-I receptor, and pappalysin 2 (PAPP-A2). Limited experience with rhIGF-I therapy in GHRD demonstrates restoration of growth that is less than seen with rhGH replacement in GH deficiency, probably due to the absence of direct effects of GH in bone and muscle.

KW - Acid labile subunit (ALS)

KW - GH-binding protein (BP)

KW - GHR gene mutation

KW - Growth hormone (GH)

KW - Insulin-like growth factor-I (IGF-I)

KW - Laron syndrome

KW - Noonan syndrome

KW - Pappalysin 2 (PAPP-A2)

KW - Protein tyrosine phosphatase non-receptor type 11 (PTPN11)

KW - Receptor (R)

KW - Recombinant human IGF-I (rhIGF-I)

KW - Serum transducers and activators of transcription 5b (STAT5b)

UR - https://www.scopus.com/pages/publications/105013011654

U2 - 10.1007/978-3-031-66296-6_2

DO - 10.1007/978-3-031-66296-6_2

M3 - Capítulo

AN - SCOPUS:105013011654

SN - 9783031662959

SP - 35

EP - 72

BT - Pediatric Endocrinology

PB - Springer Nature

ER -

Growth Hormone Insensitivity

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this